Imunon, Inc. (NASDAQ:IMNN) Stock Short Interest Report for October

Imunon, Inc. (NASDAQ:IMNN) saw a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 62,366 shares, a decrease of 64.0% from the September 30th total of 173,197 shares. Based on an average daily volume of 92,780 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.1% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Imunon Stock Up 0.3%

NASDAQ IMNN traded up $0.00 on Thursday, reaching $0.83. 209,342 shares of the stock traded hands, compared to its average volume of 101,506. Imunon has a 12 month low of $0.81 and a 12 month high of $4.79. The company has a market cap of $4.67 million, a price-to-earnings ratio of -0.22 and a beta of 2.01. The company has a fifty day moving average price of $1.34 and a 200-day moving average price of $2.27. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.82 and a current ratio of 1.82.

Imunon (NASDAQ:IMNN) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.33. As a group, research analysts forecast that Imunon will post -2.37 EPS for the current fiscal year.

About Imunon

Imunon, Inc (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells.

Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies.